protagonist-therapeutics
(2)
Barry Selick’s Second Act Is a Return to the Bench-to-Business Handoff
After decades moving between lab science, venture capital, public-company leadership and university innovation, Barry Selick is back inside a small biotech - carrying a career’s worth of pattern recognition into Hinge Bio’s clinical turn.
Dinesh V. Patel
Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.